EIGR Eiger BioPharmaceuticals, Inc. Stock Quote

EIGR [NASD]

Index	-	P/E	-	EPS (ttm)	-2.32	Insider Own	1.10%	Shs Outstand	33.89M	Perf Week	-2.19%
Market Cap	291.97M	Forward P/E	-	EPS next Y	-1.74	Insider Trans	-0.31%	Shs Float	31.98M	Perf Month	1.07%
Income	-65.10M	PEG	-	EPS next Q	-0.54	Inst Own	71.20%	Short Float	4.56%	Perf Quarter	-30.01%
Sales	-	P/S	-	EPS this Y	25.00%	Inst Trans	-5.45%	Short Ratio	6.58	Perf Half Y	-6.08%
Book/sh	3.72	P/B	2.28	EPS next Y	-28.80%	ROA	-	Target Price	-	Perf Year	-19.60%
Cash/sh	4.67	P/C	1.82	EPS next 5Y	-	ROE	-	52W Range	7.57 - 13.99	Perf YTD	-30.92%
Dividend	-	P/FCF	-	EPS past 5Y	48.20%	ROI	-	52W High	-39.31%	Beta	1.34
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	-	52W Low	12.15%	ATR	0.52
Employees	28	Current Ratio	9.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.66	Volatility	8.79% 6.10%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.53	Prev Close	8.54
Shortable	Yes	LT Debt/Eq	0.25	Earnings	May 06 AMC	Payout	-	Avg Volume	221.46K	Price	8.49
Recom	1.00	SMA20	-0.50%	SMA50	-5.61%	SMA200	-14.82%	Volume	117,647	Change	-0.59%

Jun-26-19

Initiated

Citigroup

Buy

$22

Jan-29-19

Initiated

Robert W. Baird

Outperform

$47

May-09-18

Initiated

B. Riley FBR, Inc.

Buy

$24

Jan-03-18

Initiated

Ladenburg Thalmann

Buy

$32

Oct-19-17

Initiated

ROTH Capital

Buy

$35

Jun-21-17

Resumed

Wedbush

Outperform

$28 → $34

May-10-21 03:41AM	Eiger BioPharmaceuticals'(NASDAQ:EIGR) Share Price Is Down 56% Over The Past Five Years. Simply Wall St.
May-06-21 04:01PM	Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update PR Newswire -6.28%
02:45PM	Eiger BioPharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 08:00AM	Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil PR Newswire
Apr-29-21 08:00AM	Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021 PR Newswire
Apr-22-21 08:00AM	Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors PR Newswire
Mar-24-21 03:55AM	Are Insiders Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock? Simply Wall St. -6.33%
Mar-09-21 06:25PM	Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates Zacks +7.40%
04:05PM	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update PR Newswire
Feb-23-21 11:07AM	Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting Benzinga
08:00AM	Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism PR Newswire
Feb-08-21 08:00AM	Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021 PR Newswire +11.39%
Jan-25-21 08:00AM	Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies PR Newswire
Jan-07-21 08:00AM	Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans PR Newswire -8.06%
Jan-06-21 11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age Barrons.com
Dec-24-20 06:49AM	Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St.
Nov-25-20 08:42AM	Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire
Nov-24-20 03:10PM	Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases Zacks -5.24%
Nov-23-20 08:00AM	Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million PR Newswire
Nov-20-20 05:53PM	Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire
07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-17-20 08:00AM	Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience 2020 PR Newswire
Nov-16-20 04:05PM	Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience 2020 PR Newswire
Nov-11-20 08:00AM	Eiger Bio to Participate in November 2020 Investor Conferences PR Newswire
Nov-05-20 04:05PM	Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire
Nov-02-20 04:30PM	Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience 2020 PR Newswire
Oct-16-20 10:01AM	Eiger (EIGR) Up on Positive Results From Coronavirus Study Zacks
Oct-15-20 03:24PM	Why Eiger BioPharmaceuticals Stock Skyrocketed Today Motley Fool +17.52%
08:00AM	Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19 PR Newswire
Sep-29-20 07:42AM	Eiger Down on Disappointing Results From Coronavirus Study Zacks
Sep-28-20 03:47PM	Why Eiger BioPharmaceuticals Stock Sank Today Motley Fool -19.51%
03:07PM	Hedge Funds Are Done Buying Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
08:00AM	Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19 PR Newswire
Sep-15-20 08:54AM	Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock Options Zacks
Sep-09-20 09:36AM	Billionaire David Shaw Pours Money Into 3 Strong Buy Stocks TipRanks
Sep-01-20 08:00AM	Eiger Bio to Participate in September 2020 Investor Conferences PR Newswire
Aug-31-20 08:00AM	Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress 2020 PR Newswire
Aug-19-20 08:49AM	Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6% Zacks
Aug-17-20 07:40AM	Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought 4.7% More Shares Simply Wall St.
Aug-06-20 04:05PM	Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Aug-03-20 08:00AM	Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences PR Newswire +10.95%
Jul-17-20 12:16PM	Is Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Popular Amongst Institutions? Simply Wall St.
Jul-12-20 08:14PM	Did Hedge Funds Make The Right Call On Eiger BioPharmaceuticals, Inc. (EIGR) ? Insider Monkey
Jul-08-20 12:00PM	Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Jun-24-20 08:32AM	Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick Zacks -7.72%
Jun-08-20 01:22PM	Hedge Funds Cant Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
May-29-20 04:05PM	Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020 PR Newswire
May-26-20 04:05PM	Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PR Newswire
May-19-20 04:05PM	Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PR Newswire
May-15-20 08:57AM	Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now? Zacks +5.21%
Apr-30-20 08:00AM	Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda PR Newswire -8.71%
Apr-22-20 10:05AM	Will Eiger BioPharmaceuticals Continue to Surge Higher? Zacks
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals +7.82%
Apr-01-20 04:05PM	Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic PR Newswire -13.24%
Mar-24-20 10:25AM	Eiger Completes NDA Submission of Progeria Drug Lonafarnib Zacks +11.88%
Mar-23-20 08:00AM	Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire +5.37%
Mar-20-20 06:45AM	Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares Simply Wall St.
Mar-13-20 08:00AM	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire +5.54%
Jan-19-20 03:04PM	Top Insider Buys Highlight for the Week of Jan. 17 GuruFocus.com
Jan-15-20 05:24AM	Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares Simply Wall St.
Jan-07-20 08:00AM	Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer PR Newswire
Jan-06-20 08:00AM	Eiger Updates on 2019 Progress and 2020 Milestones Expected PR Newswire
Dec-16-19 05:15PM	Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire
Dec-07-19 01:33AM	Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Nov-15-19 08:00AM	Eiger to Present at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 08:45AM	Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 PR Newswire
Nov-11-19 09:58AM	Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy? Insider Monkey
Nov-07-19 04:05PM	Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
Oct-21-19 09:00AM	Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019 PR Newswire
Oct-09-19 09:47AM	Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St.
Sep-27-19 08:00AM	Eiger to Present at Cantor 2019 Global Healthcare Conference PR Newswire
Aug-29-19 04:05PM	Eiger BioPharmaceuticals to Participate in September Conferences PR Newswire
Aug-20-19 08:00AM	Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection PR Newswire
Aug-08-19 04:05PM	Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Aug-05-19 08:00AM	Eiger BioPharmaceuticals to Participate in Investor Conferences in August PR Newswire -6.37%
Jul-31-19 08:00AM	Immunotherapy startup names new CEO American City Business Journals
Jul-18-19 09:20AM	Small Peninsula biotech targets big impact on deadly childhood aging disease American City Business Journals
Jul-11-19 12:42PM	Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares Simply Wall St.
Jul-08-19 09:00AM	What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks +12.97%
Jun-20-19 07:08PM	Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Jun-18-19 07:31AM	The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 04:16PM	Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Jun-10-19 08:00AM	Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PR Newswire
Jun-05-19 08:00AM	Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PR Newswire
May-30-19 08:00AM	Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 04:05PM	Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PR Newswire
May-09-19 05:04PM	Eiger BioPharma: 1Q Earnings Snapshot Associated Press
04:01PM	Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
Apr-30-19 08:00AM	Eiger to Present at ChinaBio® Partnering Forum 2019 PR Newswire
Apr-26-19 02:43PM	Do Institutions Own Shares In Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)? Simply Wall St.
Apr-23-19 03:50PM	Weekly CFO Buys Highlight GuruFocus.com
Apr-17-19 10:53PM	Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire -5.72%
04:01PM	Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Apr-15-19 08:00AM	Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PR Newswire
Apr-11-19 04:05PM	Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress 2019 PR Newswire
Mar-26-19 08:00AM	Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-25-19 01:30PM	Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 PR Newswire
Mar-20-19 08:00AM	Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PR Newswire
Mar-15-19 09:04AM	What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks
Mar-14-19 04:19PM	Eiger BioPharma: 4Q Earnings Snapshot Associated Press

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dietz Thomas John	Director	Apr 09	Buy	8.49	2,500	21,220	37,500	Apr 12 06:10 PM
Loh Evan	Director	Mar 15	Sale	10.14	2,000	20,280	8,000	Mar 15 07:30 PM
Mayer Eldon C. III	Ex VP & Chief Commerc. Officer	Jan 08	Sale	11.68	1,690	19,739	35,810	Jan 11 06:10 PM
Glenn Jeffrey S	Director	Aug 12	Buy	11.42	5,000	57,103	5,000	Aug 12 06:28 PM
Glenn Jeffrey S	Director	Aug 11	Buy	11.49	5,000	57,463	71,355	Aug 12 06:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience